Hallmarks of cancer: the next generation.

PubWeight™: 140.01‹?› | Rank: Top 0.01% | All-Time Top 100

🔗 View Article (PMID 21376230)

Published in Cell on March 04, 2011

Authors

Douglas Hanahan1, Robert A Weinberg

Author Affiliations

1: The Swiss Institute for Experimental Cancer Research (ISREC), School of Life Sciences, EPFL, Lausanne CH-1015, Switzerland. dh@epfl.ch

Associated clinical trials:

Ganetespib and Ziv-Aflibercept in Refractory Gastrointestinal Carcinomas, Non-Squamous Non-Small Cell Lung Carcinomas, Urothelial Carcinomas, and Sarcomas | NCT02192541

The Utility of Circulating Tumour Cells and Plasma microRNA in Esophageal Adenocarcinoma | NCT02812680

Impact of Dietary Intervention on Tumor Immunity: the DigesT Trial (DIgesT) | NCT03454282

Drivers of Hypoxia-induced Angiogenesis in Tumor Development | NCT03979833

Efficacy of metfOrmin in PrevenTIng Glucocorticoid-induced Diabetes in Patients With Brain Metastases (OPTIMAL) | NCT04001725

Nutritional Status in Locally Advanced or Metastatic Solid Cancer Patients in Spain: the NutriOncoSearch (NOS) Study (NOS) | NCT04168814

Articles citing this

(truncated to the top 100)

Comprehensive genomic characterization of squamous cell lung cancers. Nature (2012) 18.90

The hallmarks of aging. Cell (2013) 14.29

Protective and pathogenic functions of macrophage subsets. Nat Rev Immunol (2011) 12.21

Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell (2012) 11.69

Discovery and saturation analysis of cancer genes across 21 tumour types. Nature (2014) 11.68

The Cancer Genome Atlas Pan-Cancer analysis project. Nat Genet (2013) 11.29

Clonal evolution in cancer. Nature (2012) 11.07

The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer (2012) 10.90

The life history of 21 breast cancers. Cell (2012) 10.59

Molecular mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell Biol (2014) 10.04

Metabolic reprogramming: a cancer hallmark even warburg did not anticipate. Cancer Cell (2012) 9.88

DNA methylation arrays as surrogate measures of cell mixture distribution. BMC Bioinformatics (2012) 9.31

EMT and dissemination precede pancreatic tumor formation. Cell (2012) 9.27

Microenvironmental regulation of tumor progression and metastasis. Nat Med (2013) 8.37

Transcriptional amplification in tumor cells with elevated c-Myc. Cell (2012) 8.24

Super-enhancers in the control of cell identity and disease. Cell (2013) 7.50

Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism. Cell (2012) 7.36

Mutual exclusivity analysis identifies oncogenic network modules. Genome Res (2011) 7.22

Neutrophils in the activation and regulation of innate and adaptive immunity. Nat Rev Immunol (2011) 6.96

Metabolite profiling identifies a key role for glycine in rapid cancer cell proliferation. Science (2012) 6.79

Clonal architecture of secondary acute myeloid leukemia. N Engl J Med (2012) 6.71

RAS oncogenes: weaving a tumorigenic web. Nat Rev Cancer (2011) 6.45

The extracellular matrix: a dynamic niche in cancer progression. J Cell Biol (2012) 6.07

Oncolytic virotherapy. Nat Biotechnol (2012) 5.79

Tumor-derived granulocyte-macrophage colony-stimulating factor regulates myeloid inflammation and T cell immunity in pancreatic cancer. Cancer Cell (2012) 5.77

Normalization of the vasculature for treatment of cancer and other diseases. Physiol Rev (2011) 5.64

The hallmarks of cancer: a long non-coding RNA point of view. RNA Biol (2012) 5.60

Stromal elements act to restrain, rather than support, pancreatic ductal adenocarcinoma. Cancer Cell (2014) 5.38

Cancer immunotherapy via dendritic cells. Nat Rev Cancer (2012) 5.37

Potential Mechanisms for Cancer Resistance in Elephants and Comparative Cellular Response to DNA Damage in Humans. JAMA (2015) 5.30

The DNA damage response and cancer therapy. Nature (2012) 5.25

APOBEC3B is an enzymatic source of mutation in breast cancer. Nature (2013) 5.18

Aging, cellular senescence, and cancer. Annu Rev Physiol (2012) 5.08

CSF-1R inhibition alters macrophage polarization and blocks glioma progression. Nat Med (2013) 5.04

Mutational inactivation of STAG2 causes aneuploidy in human cancer. Science (2011) 5.04

A novel retinoblastoma therapy from genomic and epigenetic analyses. Nature (2012) 5.02

PI3K and cancer: lessons, challenges and opportunities. Nat Rev Drug Discov (2014) 4.81

Modulation of oxidative stress as an anticancer strategy. Nat Rev Drug Discov (2013) 4.72

An APOBEC cytidine deaminase mutagenesis pattern is widespread in human cancers. Nat Genet (2013) 4.69

Tumor-associated macrophages: from mechanisms to therapy. Immunity (2014) 4.69

The microcosmos of cancer. Nature (2012) 4.50

T-helper-1-cell cytokines drive cancer into senescence. Nature (2013) 4.47

Circulating tumor cell clusters are oligoclonal precursors of breast cancer metastasis. Cell (2014) 4.44

Interpreting cancer genomes using systematic host network perturbations by tumour virus proteins. Nature (2012) 4.35

Mutant p53: one name, many proteins. Genes Dev (2012) 4.33

Normalizing tumor microenvironment to treat cancer: bench to bedside to biomarkers. J Clin Oncol (2013) 4.23

Inflammation-induced cancer: crosstalk between tumours, immune cells and microorganisms. Nat Rev Cancer (2013) 4.02

Neutralizing tumor-promoting chronic inflammation: a magic bullet? Science (2013) 3.91

Targeting IAP proteins for therapeutic intervention in cancer. Nat Rev Drug Discov (2012) 3.88

Transient low doses of DNA-demethylating agents exert durable antitumor effects on hematological and epithelial tumor cells. Cancer Cell (2012) 3.82

The genomic and transcriptomic landscape of a HeLa cell line. G3 (Bethesda) (2013) 3.82

Immunogenic cell death and DAMPs in cancer therapy. Nat Rev Cancer (2012) 3.76

The diverse and complex roles of NF-κB subunits in cancer. Nat Rev Cancer (2012) 3.75

PGC1α expression defines a subset of human melanoma tumors with increased mitochondrial capacity and resistance to oxidative stress. Cancer Cell (2013) 3.71

Cancer genetics and epigenetics: two sides of the same coin? Cancer Cell (2012) 3.65

Epithelial-mesenchymal plasticity in carcinoma metastasis. Genes Dev (2013) 3.63

A microRNA regulon that mediates endothelial recruitment and metastasis by cancer cells. Nature (2011) 3.60

The secret ally: immunostimulation by anticancer drugs. Nat Rev Drug Discov (2012) 3.60

Genome-wide CRISPR screen in a mouse model of tumor growth and metastasis. Cell (2015) 3.58

The dynamic nature of autophagy in cancer. Genes Dev (2011) 3.57

Tumor-infiltrating DCs suppress nucleic acid-mediated innate immune responses through interactions between the receptor TIM-3 and the alarmin HMGB1. Nat Immunol (2012) 3.57

Glutamine and cancer: cell biology, physiology, and clinical opportunities. J Clin Invest (2013) 3.46

Targeting natural killer cells and natural killer T cells in cancer. Nat Rev Immunol (2012) 3.43

Recurrent hemizygous deletions in cancers may optimize proliferative potential. Science (2012) 3.41

Dissecting the tumor myeloid compartment reveals rare activating antigen-presenting cells critical for T cell immunity. Cancer Cell (2014) 3.40

A mitochondrial pyruvate carrier required for pyruvate uptake in yeast, Drosophila, and humans. Science (2012) 3.39

ROS function in redox signaling and oxidative stress. Curr Biol (2014) 3.35

Selection of bone metastasis seeds by mesenchymal signals in the primary tumor stroma. Cell (2013) 3.33

Taking aim at the extracellular matrix: CCN proteins as emerging therapeutic targets. Nat Rev Drug Discov (2011) 3.26

Cumulative haploinsufficiency and triplosensitivity drive aneuploidy patterns and shape the cancer genome. Cell (2013) 3.26

Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors. Cancer Discov (2013) 3.25

Engineered SIRPα variants as immunotherapeutic adjuvants to anticancer antibodies. Science (2013) 3.25

Genetic heterogeneity of diffuse large B-cell lymphoma. Proc Natl Acad Sci U S A (2013) 3.25

Evolution of the cancer genome. Nat Rev Genet (2012) 3.24

Towards the introduction of the 'Immunoscore' in the classification of malignant tumours. J Pathol (2014) 3.21

HIV latency. Proliferation of cells with HIV integrated into cancer genes contributes to persistent infection. Science (2014) 3.17

Network-based stratification of tumor mutations. Nat Methods (2013) 3.12

Combinatorial drug therapy for cancer in the post-genomic era. Nat Biotechnol (2012) 3.10

Dysregulated pH: a perfect storm for cancer progression. Nat Rev Cancer (2011) 3.10

Discovery of small molecules that bind to K-Ras and inhibit Sos-mediated activation. Angew Chem Int Ed Engl (2012) 3.09

Combining radiotherapy and cancer immunotherapy: a paradigm shift. J Natl Cancer Inst (2013) 3.07

Epithelial cell polarity, stem cells and cancer. Nat Rev Cancer (2011) 3.06

Interplay between the cancer genome and epigenome. Cell (2013) 3.05

Suppression of autophagy by FIP200 deletion inhibits mammary tumorigenesis. Genes Dev (2011) 3.05

Cancer cell metabolism: one hallmark, many faces. Cancer Discov (2012) 3.03

Functional impact bias reveals cancer drivers. Nucleic Acids Res (2012) 2.96

Oncogenic Kras is required for both the initiation and maintenance of pancreatic cancer in mice. J Clin Invest (2012) 2.95

Inferring tumour purity and stromal and immune cell admixture from expression data. Nat Commun (2013) 2.94

Pan-cancer network analysis identifies combinations of rare somatic mutations across pathways and protein complexes. Nat Genet (2014) 2.91

Cellular metabolism and disease: what do metabolic outliers teach us? Cell (2012) 2.90

Pathogenic mechanisms in HBV- and HCV-associated hepatocellular carcinoma. Nat Rev Cancer (2013) 2.87

Analysis of tumor metabolism reveals mitochondrial glucose oxidation in genetically diverse human glioblastomas in the mouse brain in vivo. Cell Metab (2012) 2.86

The microbiome and cancer. Nat Rev Cancer (2013) 2.86

Control-FREEC: a tool for assessing copy number and allelic content using next-generation sequencing data. Bioinformatics (2011) 2.86

Choline metabolism in malignant transformation. Nat Rev Cancer (2011) 2.85

XBP1 promotes triple-negative breast cancer by controlling the HIF1α pathway. Nature (2014) 2.84

The neutrophil in vascular inflammation. Nat Med (2011) 2.84

On PAR with PARP: cellular stress signaling through poly(ADP-ribose) and PARP-1. Genes Dev (2012) 2.82

Regulating the regulator: post-translational modification of RAS. Nat Rev Mol Cell Biol (2011) 2.81

The histone deacetylase SIRT6 is a tumor suppressor that controls cancer metabolism. Cell (2012) 2.78

Articles by these authors

The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell (2008) 46.08

The basics of epithelial-mesenchymal transition. J Clin Invest (2009) 32.82

Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell (2004) 31.38

Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature (2007) 21.53

Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat Rev Cancer (2009) 18.53

Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell (2005) 18.20

An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors. Nat Genet (2008) 17.67

Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature (2007) 15.20

Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis. Dev Cell (2008) 14.80

A perspective on cancer cell metastasis. Science (2011) 13.31

Retracted A pleiotropically acting microRNA, miR-31, inhibits breast cancer metastasis. Cell (2009) 10.51

Tumor metastasis: molecular insights and evolving paradigms. Cell (2011) 10.34

A progression puzzle. Nature (2002) 9.56

Lentivirus-delivered stable gene silencing by RNAi in primary cells. RNA (2003) 8.07

Reconstruction of functionally normal and malignant human breast tissues in mice. Proc Natl Acad Sci U S A (2004) 7.96

Loss of E-cadherin promotes metastasis via multiple downstream transcriptional pathways. Cancer Res (2008) 7.91

Ras oncogenes: split personalities. Nat Rev Mol Cell Biol (2008) 7.91

miR-9, a MYC/MYCN-activated microRNA, regulates E-cadherin and cancer metastasis. Nat Cell Biol (2010) 6.67

Core epithelial-to-mesenchymal transition interactome gene-expression signature is associated with claudin-low and metaplastic breast cancer subtypes. Proc Natl Acad Sci U S A (2010) 6.15

Normal and neoplastic nonstem cells can spontaneously convert to a stem-like state. Proc Natl Acad Sci U S A (2011) 5.53

Modelling the molecular circuitry of cancer. Nat Rev Cancer (2002) 5.43

Mesenchyme Forkhead 1 (FOXC2) plays a key role in metastasis and is associated with aggressive basal-like breast cancers. Proc Natl Acad Sci U S A (2007) 5.24

Cancer stem cells: mirage or reality? Nat Med (2009) 5.20

The signals and pathways activating cellular senescence. Int J Biochem Cell Biol (2004) 5.00

Rules for making human tumor cells. N Engl J Med (2002) 4.84

Therapeutic silencing of miR-10b inhibits metastasis in a mouse mammary tumor model. Nat Biotechnol (2010) 4.80

Paracrine and autocrine signals induce and maintain mesenchymal and stem cell states in the breast. Cell (2011) 4.79

Enumeration of the simian virus 40 early region elements necessary for human cell transformation. Mol Cell Biol (2002) 4.77

Slug and Sox9 cooperatively determine the mammary stem cell state. Cell (2012) 4.77

The melanocyte differentiation program predisposes to metastasis after neoplastic transformation. Nat Genet (2005) 4.70

Stromal fibroblasts in cancer: a novel tumor-promoting cell type. Cell Cycle (2006) 4.67

Transformation of different human breast epithelial cell types leads to distinct tumor phenotypes. Cancer Cell (2007) 4.30

Species- and cell type-specific requirements for cellular transformation. Cancer Cell (2004) 4.25

Cancer stem cells and epithelial-mesenchymal transition: concepts and molecular links. Semin Cancer Biol (2012) 3.98

Exploring a new twist on tumor metastasis. Cancer Res (2006) 3.96

The epigenetics of epithelial-mesenchymal plasticity in cancer. Nat Med (2013) 3.96

Systemic endocrine instigation of indolent tumor growth requires osteopontin. Cell (2008) 3.95

Immortalization and transformation of primary human airway epithelial cells by gene transfer. Oncogene (2002) 3.80

Growth-inhibitory and tumor- suppressive functions of p53 depend on its repression of CD44 expression. Cell (2008) 3.75

The Spemann organizer gene, Goosecoid, promotes tumor metastasis. Proc Natl Acad Sci U S A (2006) 3.64

Poised chromatin at the ZEB1 promoter enables breast cancer cell plasticity and enhances tumorigenicity. Cell (2013) 3.61

Retracted Ras modulates Myc activity to repress thrombospondin-1 expression and increase tumor angiogenesis. Cancer Cell (2003) 3.56

Telomerase maintains telomere structure in normal human cells. Cell (2003) 3.29

Opinion: Comparative biology of mouse versus human cells: modelling human cancer in mice. Nat Rev Cancer (2003) 3.23

Enrichment of a population of mammary gland cells that form mammospheres and have in vivo repopulating activity. Cancer Res (2007) 3.04

Autocrine TGF-beta and stromal cell-derived factor-1 (SDF-1) signaling drives the evolution of tumor-promoting mammary stromal myofibroblasts. Proc Natl Acad Sci U S A (2010) 3.03

Telomeres: cancer to human aging. Annu Rev Cell Dev Biol (2006) 2.88

Telomerase contributes to tumorigenesis by a telomere length-independent mechanism. Proc Natl Acad Sci U S A (2002) 2.82

Integrin beta1-focal adhesion kinase signaling directs the proliferation of metastatic cancer cells disseminated in the lungs. Proc Natl Acad Sci U S A (2009) 2.75

Tumor-host interactions: a far-reaching relationship. J Clin Oncol (2010) 2.48

Epithelial mesenchymal transition traits in human breast cancer cell lines parallel the CD44(hi/)CD24 (lo/-) stem cell phenotype in human breast cancer. J Mammary Gland Biol Neoplasia (2010) 2.38

When cells get stressed: an integrative view of cellular senescence. J Clin Invest (2004) 2.37

A mouse model of human breast cancer metastasis to human bone. Cancer Res (2005) 2.24

Adaptation versus selection: the origins of metastatic behavior. Cancer Res (2007) 2.08

Micromanagers of malignancy: role of microRNAs in regulating metastasis. Trends Genet (2008) 2.03

Taking the study of cancer cell survival to a new dimension. Cell (2002) 2.03

Human tumors instigate granulin-expressing hematopoietic cells that promote malignancy by activating stromal fibroblasts in mice. J Clin Invest (2011) 1.96

Protein kinase C α is a central signaling node and therapeutic target for breast cancer stem cells. Cancer Cell (2013) 1.86

IGF-2 is a mediator of prolactin-induced morphogenesis in the breast. Dev Cell (2002) 1.79

Phenotypic plasticity and epithelial-mesenchymal transitions in cancer and normal stem cells? Int J Cancer (2011) 1.79

Erosion of the telomeric single-strand overhang at replicative senescence. Nat Genet (2003) 1.78

Cell plasticity and heterogeneity in cancer. Clin Chem (2012) 1.74

Retracted Concomitant suppression of three target genes can explain the impact of a microRNA on metastasis. Genes Dev (2009) 1.74

MicroRNAs in malignant progression. Cell Cycle (2007) 1.74

Retracted Concurrent suppression of integrin alpha5, radixin, and RhoA phenocopies the effects of miR-31 on metastasis. Cancer Res (2010) 1.73

Cancer-stimulated mesenchymal stem cells create a carcinoma stem cell niche via prostaglandin E2 signaling. Cancer Discov (2012) 1.71

Systemic stromal effects of estrogen promote the growth of estrogen receptor-negative cancers. Cancer Res (2007) 1.66

MicroRNAs: Crucial multi-tasking components in the complex circuitry of tumor metastasis. Cell Cycle (2009) 1.63

Heart and liver defects and reduced transforming growth factor beta2 sensitivity in transforming growth factor beta type III receptor-deficient embryos. Mol Cell Biol (2003) 1.59

miR-31: a crucial overseer of tumor metastasis and other emerging roles. Cell Cycle (2010) 1.51

The outgrowth of micrometastases is enabled by the formation of filopodium-like protrusions. Cancer Discov (2012) 1.45

Continuous elimination of oxidized nucleotides is necessary to prevent rapid onset of cellular senescence. Proc Natl Acad Sci U S A (2008) 1.41

Retracted Activation of miR-31 function in already-established metastases elicits metastatic regression. Genes Dev (2011) 1.40

An integrin-linked machinery of cytoskeletal regulation that enables experimental tumor initiation and metastatic colonization. Cancer Cell (2013) 1.36

Metastatic colonization: settlement, adaptation and propagation of tumor cells in a foreign tissue environment. Semin Cancer Biol (2010) 1.36

Roles for microRNAs in the regulation of cell adhesion molecules. J Cell Sci (2011) 1.25

Heterogeneity of stromal fibroblasts in tumors. Cancer Biol Ther (2007) 1.21

Chemokine networks and breast cancer metastasis. Breast Dis (2007) 1.17

AACR special conference on epithelial-mesenchymal transition and cancer progression and treatment. Cancer Res (2010) 1.17

Coevolution in the tumor microenvironment. Nat Genet (2008) 1.16

Senescence: does it all happen at the ends? Oncogene (2002) 0.98

High efficiency creation of human monoclonal antibody-producing hybridomas. J Immunol Methods (2004) 0.94

Assaying microRNA loss-of-function phenotypes in mammalian cells: emerging tools and their potential therapeutic utility. RNA Biol (2009) 0.90

Of mice and (wo)men: mouse models of breast cancer metastasis to bone. J Bone Miner Res (2010) 0.89

Functional genomics and the breast cancer problem. Cancer Cell (2002) 0.86

Cancer cell of origin: spotlight on luminal progenitors. Cell Stem Cell (2010) 0.83

Filling the mosaic of p53 actions: p53 represses RHAMM expression. Cell Cycle (2008) 0.82

Poised with purpose: cell plasticity enhances tumorigenicity. Cell Cycle (2013) 0.81

Is metastasis predetermined? Mol Oncol (2007) 0.81

Cancer Biology and Therapy: the road ahead. Cancer Biol Ther (2002) 0.81

Metastasis suppression: a role of the Dice(r). Genome Biol (2010) 0.78

Retrospective: Judah Folkman (1933-2008). Science (2008) 0.77

Addendum: A breast cancer stem cell niche supported by juxtacrine signalling from monocytes and macrophages. Nat Cell Biol (2015) 0.76

All You Need Is Mentorship. Cell (2016) 0.75

Health for life. Your lifestyle, your genes, and cancer. Newsweek (2008) 0.75